APP and Alzheimer disease: This was confirmed 10 years later in the more-commonly used APP/PS1 transgenic mouse model of AD, in which 2-AG levels were increased in the cortex although that occurred upon inhibition of its degrading enzyme, monoacylglycerol lipase (MAGL) [52].